Completed PHASE2 INTERVENTIONAL 2-arm NCT02015312

A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) (TAME-AL)

A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)

Sponsor: Florian Michel

Conditions Cardiac Involvement Light Chain (AL) Amyloidosis

Interventions Epigallocatechin-3-gallate (EGCG) Placebo

Updated 6 times since 2017 Last updated: Oct 16, 2017 Started: Apr 30, 2013 Primary completion: Oct 11, 2017 Completion: Oct 11, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02015312, this PHASE2 trial focuses on Cardiac Involvement and Light Chain (AL) Amyloidosis and remains completed. Sponsored by Florian Michel, it has been updated 6 times since 2013, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Nov 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Nov 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Florian Michel
German Federal Ministry of Education and Research

Data source: University Hospital Heidelberg

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Heidelberg, Germany